A phase 1 trial of Apta-1
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Apta 1 (Primary)
- Indications Sepsis
- Focus Adverse reactions; First in man
- Sponsors Aptahem
- 08 Feb 2019 According to an Aptahem media release, the delivery of its drug product will be delayed due to some technical difficulties encountered during the contract manufacturer's production. As a consequence, the company anticipates commencement of the planned clinical study for Apta-1 will be delayed.
- 10 Oct 2018 According to an Aptahem media release, this trial is expected to start in the third quarter of 2019.
- 27 Jun 2018 According to an Aptahem media release, YA II PN Ltd will provide the funds for this phase 1 first in man study.